Central nervous system (CNS) metastasis from nasopharyngeal carcinoma is an extremely rare event.
INTRODUCTION
N asopharyngeal cancer (NPC) is the head and neck cancer with the highest incidence of distant spread. The commonest distant metastatic sites are reported to be in the bone, lung and liver in descending order, in the literature (1) . While intracranial invasion by direct extension from the nasopharynx is a common finding in locally advanced NPC, CNS metastasis of NPC is an extremely rare occurrence (2, 3) . Moreover, the majority of CNS metastases reported in the literature diagnosed in the spinal cord and commonly occurred as a component of disseminated disease (3) (4) (5) (6) (7) .
Among 283 non-metastatic NPC patients treated at our department between 1993 and 2002, 52 (18%) developed distant metastasis in 60 sites in the follow up. The sites of distant metastasis included bone in 34 patients, lung in 12 patients, liver in 6 patients, lymph nodes in 4 patients, choroid in 1, and brain in 1 patient. Previously, we reported the case with choroid metastasis, which is also a rare occurrence (8) . Here, we present a patient who had isolated CNS metastasis 45 months after successful treatment of primary disease.
To the best of our knowledge, the present case is the first case with isolated CNS metastasis from NPC in the English literature.
CASE PRESENTATION
A 41-year-old male was diagnosed with T1N3aM0 -Stage IVB NPC according to the 1997 AJCC Staging System. (9) A magnetic resonance imaging (MRI) scan and fiber optic endoscopy revealed a small primary tumor in nasopharynx and the biopsy revealed undifferentiated carcinoma of the nasopharynx. There was a metastatic lymph node measuring 8 cm in greatest dimension that was palpable in the right neck. Three cycles of cisplatinbased combined chemotherapy regimen (cisplatin, 5-flourouracil) were given prior to radiotherapy and a complete response was obtained at both primary site and in the neck. Original diagnosis of the nasopharyngeal mass made in 1997 was confirmed to be undifferentiated nasopharyngeal carcinoma, which has similar morphological characteristics as the metastatic carcinoma to the brain. No other metastatic lesion was detected in the systemic workup. The patient was treated with whole brain radiotherapy to a total dose of 3000 cGy in 10 fractions.
DISCUSSION
Though intracranial invasion by direct extension of locally advanced disease is not uncommon, metastases to the CNS, either through hematogenous route or through the cerebrospinal fluid (CSF), from NPC have rarely been reported (3,10). There have been several case reports of spinal cord metastases, all of which associated with locally advanced disease (3-7). The possible mechanism of metastases was hypothesized to be dissemination through CSF. In the two patients with brain metastases mentioned in the literature, widespread systemic metastases were also reported (3, 10) . The present case was the first to present with isolated CNS metastasis of a NPC with T1 primary tumor. Since the blood brain barrier is not anticipated to be disrupted at this early stage of illness and no local recurrence was observed, hematogenous route rather than dissemination through CSF is considered to be the possible mechanism. In the above-mentioned two case reports, metastatic lesions have been reported to be located in the occipital lobes (3, 10) . In the present case, metastatic lesion was located in the temporal lobe. There is no known lymphatic or vascular connection between the nasopharynx and temporal lobes. Ngan and colleagues, discussing the same issue for the patients who had occipital metastases, hypothesized that microenvironment in the occipital lobes might have facilitated the metastatic tumor cells to localize in that region. The present case has shown that the occipital lobes are not the only sites for NPC cells to metastasize. Distant metastasis to only one organ/site has been reported to be related to favorable prognosis independent of the number of metastases (1). Status Figure1c. T2-weighted axial image shows the mass is hypointens relative to the gray matter and edema is hyperintense around the mass of primary tumor, evidences of disseminated disease, performance status of the patient, treatment modalities already applied to the patient, histopathology of the tumor, and symptoms related to brain metastases are factors effecting the therapeutic management. It is important to mention that NPC patients with CNS metastasis in the literature had had pulmonary and liver metastasis before developing CNS metastases. (3, 5, 6, 10) This association suggests the hematogenous route of occurrence in majority of metastases of the CNS.
As all of the patients with metastasis to the brain have accompanying widespread systemic disease, systemic therapy can be a good treatment option affecting all metastatic disease in the body. But the chance of effect from further systemic therapy is limited, as most of the patients have already been treated with chemotherapy. Since there was no locoregional recurrence when the patient presented with isolated CNS metastasis, total excision of the metastatic tumor and postoperative radiotherapy were planned to gain a better survival.
